BCL2L1 and neoplasm: According to this analysis, EVs derived from NR patients carry previously reported tumor biomarker candidates such as: FAS, RET, STAT5, TNFRSF1B, WNT1, ABCB1, CASP5, CCND1, FGF1, ABL1, BCL2L1, PRIM1, CD4, HSP90AA1 and HSP90AB1, while BAX, CASP3, HDAC1, NGFR, TNFSF11, TP73, BRCA2, EGFR, IKBKB, STAT1, SNAI1, BAG1 and TNFRSF10B were detected in EVs from CR patients.